Mariners Gamble on Effross: A Bullpen Depth Play Without Upside

The Mariners signed reliever Scott Effross to a minor league contract on Tuesday, with the 32-year-old reporting to Triple-A Tacoma. It's a low-cost flier on a pitcher who spent the 2026 season bouncing through Detroit's farm system before the Tigers released him last week.

Effross carries injury baggage that explains why he remains unsigned past mid-August. Tommy John surgery cost him all of 2023. Back surgery over the 2023-24 offseason delayed his return until September 2024. A hamstring strain ate into last season, pushing him into a depth role for the Yankees—10 2/3 innings in a bullpen that didn't protect him in free agency. He's now looking for his fifth MLB season after a promising 2022 rookie year with the Cubs, when he arrived mid-season via trade from Detroit and showed enough to catch the Yankees' attention. That outlier year masks what's actually in front of Seattle: a 32-year-old sidearmer with a 4.46 ERA across 36 1/3 Triple-A innings this year, paired with a 16% strikeout rate and league-average 42% ground-ball rate. Neither metric suggests he's rediscovered velocity or movement.

Seattle's bullpen context makes the move tactical but not transformative. The Mariners rank 11th in team ERA and 13th in strikeout rate, and a home-run spike has ballooned their ERA to 5.02 over the last month. The loss of Cole Wilcox to an oblique strain opened middle relief real estate. Effross profiles as organizational filler—a third or fourth option for a team that's already cycling through depth. He won't move the needle on team pitching totals or reliever strikeout props. The path to the majors exists, but it's narrow: he'd need to reverse four years of injury-plagued decline in a handful of minor league appearances, then outpitch other waiver-eligible arms already on the 40-man roster.

From a betting angle, Effross's arrival changes almost nothing. Mariners bullpen outs and strikeout rate props remain pinned to the existing rotation quality and higher-leverage arms. If Effross reaches the majors—a 20-30% probability at best given the timeline and his performance floor—he'll enter as a mop-up option or low-leverage situational piece. The market hasn't and won't price him into meaningful team totals. The real Seattle story is the gap between talent expectation (a division contender) and execution (11th-ranked bullpen ERA); a Triple-A signing doesn't close that gap.